|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2006-9-4
|
|
pubmed:abstractText |
Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous cell carcinoma (HNSCC) where expression levels correlate with decreased survival. Therapies that block EGFR have shown limited efficacy in clinical trials and primarily when combined with standard therapy. The most common form of mutant EGFR (EGFRvIII) has been described in several cancers, chiefly glioblastoma. The present study was undertaken to determine the incidence of EGFRvIII expression in HNSCC and the biological consequences of EGFRvIII on tumor growth in response to EGFR targeting.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BignerDarell DDD,
pubmed-author:CoppelliFrancesca MFM,
pubmed-author:FreilinoMaria LML,
pubmed-author:FurnariFrank BFB,
pubmed-author:GoodingWilliam EWE,
pubmed-author:GrandisJennifer RJR,
pubmed-author:GranerMichael WMW,
pubmed-author:HuntJennifer LJL,
pubmed-author:LangoMiriam NMN,
pubmed-author:SokJohn CJC,
pubmed-author:ThomasSufi MSM,
pubmed-author:WikstrandCarol JCJ,
pubmed-author:XiSichuanS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5064-73
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16951222-Adult,
pubmed-meshheading:16951222-Aged,
pubmed-meshheading:16951222-Aged, 80 and over,
pubmed-meshheading:16951222-Animals,
pubmed-meshheading:16951222-Antibodies, Monoclonal,
pubmed-meshheading:16951222-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16951222-Carcinoma, Squamous Cell,
pubmed-meshheading:16951222-Cell Line, Tumor,
pubmed-meshheading:16951222-Cell Proliferation,
pubmed-meshheading:16951222-Drug Resistance, Neoplasm,
pubmed-meshheading:16951222-Female,
pubmed-meshheading:16951222-Gene Expression Profiling,
pubmed-meshheading:16951222-Head and Neck Neoplasms,
pubmed-meshheading:16951222-Humans,
pubmed-meshheading:16951222-Male,
pubmed-meshheading:16951222-Mice,
pubmed-meshheading:16951222-Mice, Nude,
pubmed-meshheading:16951222-Middle Aged,
pubmed-meshheading:16951222-Mutation,
pubmed-meshheading:16951222-Neoplasm Transplantation,
pubmed-meshheading:16951222-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16951222-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:16951222-Transplantation, Heterologous
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
|
|
pubmed:affiliation |
Department of Otolaryngology, and University of Pittsburgh Cancer Institute Biostatistics, University of Pittsburgh, Pennsylvania 15213, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
